Futura Medical is developing a portfolio of innovative products for two large markets, sexual health and pain.
We have four products in late-stage development, with MED3000 being the lead product.
MED3000 is a topical gel which utilises our proprietary DermaSys® technology, and was developed specifically for the treatment of ED.
Topical treatment for erectile dysfunction
CE mark granted as a medical device in the EU. Clear regulatory pathway as a medical device in the US with FDA endorsement of Phase 3 clinical study protocol FM71. First deal signed for China and South East Asia with discussions ongoing for the licensing rights in other territories as part of an agreed process managed by Futura’s advisers.
Topical diclofenac pain relief gel
Scientific advisory meeting held with MHRA confirming the need of a Phase 3 study to support the improved skin permeation, including potential superior efficacy claims. Exploring the feasibility of a clinical study to satisfy the Phase 3 requirements for both UK and US approval.
Topical cannabidiol formulation
Joint venture collaboration. Early development stage completed. IP application filed. Advisers recently retained to explore commercial opportunities.